Ongoing in vivo pre-clinical work will help elucidate the various contributions of UCHL5 toward TGF-β signaling, clarifying the ultimate outcome and potential benefits of inhibition of UCHL5 in patients with ovarian cancer. This evidence concerns the gene TGFB1 and ovarian carcinoma.